Tag: Mm 120

In recent decades, significant innovation in anxiety treatment has been limited, with the last major indication approval for generalized anxiety disorder (GAD) occurring almost two decades ago. Now, however, the landscape is changing, bringing new hope as researchers and drug developers actively pursue what is the breakthrough drug for anxiety. The most prominent new candidate is MM-120, a psychoactive compound derived from LSD, which has received FDA Breakthrough Therapy designation for GAD.

In August 2023, the FDA approved Zurzuvae (zuranolone) for postpartum depression, marking one of the most recent and novel pharmacological advancements related to anxiety and depression. This development, alongside breakthrough designations for compounds like MM-120, indicates a new era for what is the newest anti-anxiety drug, moving beyond traditional classes toward more targeted approaches.